Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

In Partnership With:

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Anastasios (Tassos) Dimou, MD, a medical oncologist at Mayo Clinic, discusses emerging treatment options in BRAF-positive lung cancer.

Standard chemotherapy and immunotherapy have demonstrated success in patients with BRAF-mutant lung cancer, explains Dimou.

Single-agent immunotherapy appears to elicit similar responses for patients with BRAF-mutant disease as it does for those in the general lung cancer population, says Dimou. Other oncogene-driven lung cancers have not shown similar responses with immunotherapy.

BRAF and MEK inhibitors that are approved in melanoma are also being actively investigated as targeted therapy in BRAF-driven lung cancer.

Although these agents have different safety profiles compared with current regimens, such as the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), they could introduce more options for patients with BRAF-positive lung cancer, concludes Dimou.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content